Brief report · 30 Jun 2026
Conference abstractPublished 2 Oct 2017
Synthesis and molecular docking of novel non-Cytotoxic, anti-Angiogenic sulfonyl coumarin derivatives against hepatocellular carcinoma cells In Vitro
National Research Centre, Egypt
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Resistance to conventional chemotherapy, leads to the need for development of novel safe and effective cancer therapies with new mechanism of action. Anti-angiogenic drugs are major example of such newly developed targeted therapeutics .In cancer drug development arena, coumarin-type compounds have been reported to bosses marked cytotoxic activities, in addition act as novel angiogenesis inhibitors. In this respect,a new series of coumarin derivatives was synthesized starting from 2-oxo-2H-coumarin-6sulfonyl chloride (1), 6-nitro-2-oxo-2H-coumarin-3-sulfonyl chloride (10) and 6-amino coumarin-2-one (19). Reaction of 1 or 10 with 2-cyanoacetohydrazide, 2`-acetyl-2-cyanoacetohydrazide or 3-amino-5-pyrazolone afforded pyrazoline derivatives. While reaction of 1 or 10 with malononitrile followed by reaction with hyadrazine hydrate, urea, thiourea or guanidine led to the formation of pyrazole and pyrimidine derivatives. On the other hand, compound 19 on reaction with VilsmeierHaack reagent yielded the corresponding aldehyde20. Compound 20 under reaction with chlorosulfonylisocyanate afforded N-chlorosulfonyl amid which cyclized to give pyranobenzothiazine derivative 25. The tested compounds 4, 5, 8, 12, 13 and 14 were non-cytotoxic against hepatocellular carcinoma cells (HepG2) using MMT. These non-cytotoxic compounds were evaluated as anti-angiogenicagent. Collectively, our results indicate that, coumarin molecules 4, 5, 8, 13 and 14 can be utilized as lead compounds to develop potential non-toxic angiogenesis inhibitors and small molecular ligands to target (HepG2), which was in concomitant with molecular docking results. 1-Acetyl-5-amino-4(2-oxo-2H-chromene-6-sulfonyl)-1,2-dihydro-pyrazol-3-one (4) considered a promising anti-angiogenic agent, where it exhibited MMP-dependent anti-migratory activity and down regulated CD105.
Subjects
ChemistryPharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Medicinal Chemistry.
Commentary · 29 Dec 2025
Accelerating Drug Discovery: Molecular Docking and Virtual Screening
Opinion · 29 Dec 2025
Pharmacophore Modeling: A Cornerstone of Drug Discovery
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalMedicinal Chemistry
- SubjectChemistry
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Eslam EL-SAWY”
- BylineArticles whose byline prints “Manal EBAID”
- BylineArticles whose byline prints “Hanaa RADY”
- BylineArticles whose byline prints “Aziza SHALBY”
- BylineArticles whose byline prints “Khadiga AHMED”
- BylineArticles whose byline prints “Heba ABO-SALEM”
